This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, W. Articles by Chiao, P. J. Search for Related Content PubMed PubMed Citation Articles by Wang, W. Articles by Chiao, P. J.

The Nuclear Factor-B RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells¹

Departments of Surgical Oncology [W. W., D. B. E., L. L., P. J. C.], Tumor Biology [P. J. C.], Gastrointestinal Medical Oncology and Digestive Diseases [J. L. A.], and Pathology [K. R. C.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

	ABSTRACT

Top ABSTRACT INTRODUCTION Materials and Methods RESULTS DISCUSSION REFERENCES

 
Pancreatic adenocarcinoma is a leading cause of adult cancer mortality in the United States. Recent studies have revealed that point mutation of the K-ras oncogene is a common event in pancreatic cancer, and oncogenesis mediated by Ras may also involve activation of Rel/nuclear factor (NF)-B transcription factors. Furthermore, the c-rel member of Rel/NF-B transcription factor family was first identified as a cellular homologue of the v-rel oncogene, suggesting that other members of the Rel/NF-B family are potentially oncogenes. We therefore investigated the possibility that Rel/NF-B transcription factors are activated in pancreatic cancer. Immunohistochemical analysis, Western blot and Northern blot analysis, electrophoretic mobility shift assays, and chloramphenicol acetyltransferase assays were performed to determine RelA activity in human pancreatic adenocarcinomas and normal tissues and nontumorigenic or tumorigenic cell lines. RelA, the p65 subunit of NF-B, was constitutively activated in 67% (16 of 24) of pancreatic adenocarcinomas but not in normal pancreatic tissues. Constitutive RelA activity was also detected in 9 of 11 human pancreatic tumor cell lines but not in nontumorigenic Syrian golden hamster cell lines. IB, a previously identified NF-B-inducible gene, was overexpressed in human pancreatic tumor tissues and cell lines, and RelA activation could be inhibited by curcumin and dominant-negative mutants of IB, raf, and MEKK1. This is the first report demonstrating constitutive activation of RelA in nonlymphoid human cancer. These data are consistent with the possibility that RelA is constitutively activated by the upstream signaling pathway involving Ras and mitogen-activated protein kinases in pancreatic tumor cells. Constitutive RelA activity may play a key role in pancreatic tumorigenesis through activation of its downstream target genes.

	INTRODUCTION

Top ABSTRACT INTRODUCTION Materials and Methods RESULTS DISCUSSION REFERENCES

 
Pancreatic adenocarcinoma is the fifth leading cause of adult cancer mortality in the United States. (1) . However, the epidemiology of pancreatic cancer provides few clues about its etiology and pathogenesis. Strategies for early detection of pancreatic cancer have not yet been developed, and most pancreatic adenocarcinomas present with metastatic or locally advanced disease at the time of diagnosis (2) . Therapeutic options for patients with advanced disease are few, because chemotherapy and irradiation are largely ineffective, and metastatic disease frequently develops even after potentially curative surgery (2, 3, 4) . Nonetheless, studies of the biology of pancreatic adenocarcinoma have revealed that activation of specific oncogenes and inactivation of specific tumor suppressor genes play critical roles (2 , 5) .

The c-rel member of Rel/NF³ -B pleiotropic transcription factors was first identified as a cellular homologue of the v-rel oncogene, indicating the possibility that other members of Rel/NF-B are oncogenes (6) . Rel/NF-B controls the expression of numerous genes involved in the immune response, embryonic development, lymphoid differentiation, oncogenesis, and apoptosis (6 , 7) . The Rel/NF-B family consists of p65, Rel (v-rel), RelB, p50 (p105), and p52 (p100), which can form heterodimers and homodimers among themselves (6 , 7) . In most cell types, Rel/NF-B proteins are sequestered in the cytoplasm in an inactive form through their noncovalent association with the inhibitor IB (8 , 9) . This association masks the nuclear localization signal of Rel/NF-B, thereby preventing Rel/NF-B nuclear translocation (8 , 9) . Activation of Rel/NF-B is controlled by IB and does not require protein synthesis, thereby allowing rapid and efficient gene regulation (6, 7, 8, 9) . Previously, we cloned IB cDNA and its promoter and described a feedback inhibition pathway to control IB gene transcription that down-regulates transient activation of Rel/NF-B (10) . We also showed that enhanced IB degradation was responsible for constitutive activation of Rel/NF-B activity in mature murine B-cell lines (11) . Stimulation of cells by various inducers that leads to phosphorylation of IB at serine residues 32 and 36 by the recently identified and cloned IB kinases, IKK1 and IKK2, triggers the rapid degradation of the inhibitor (12, 13, 14, 15, 16, 17, 18, 19) . Consequently, Rel/NF-B proteins are released and translocated into the nucleus, where they activate the expression of target genes. MEKK1, a kinase involved in TNF--induced NF-B activation, was identified as one of the tightly associated subunits in IB kinase complex and activates the IB kinase complex by phosphorylation (15 , 20 , 21) . These findings have provided functional analysis of components of an IB kinase complex for a better understanding of the signal transduction cascade leading to activation of Rel/NF-B.

Several reports suggest that members of the Rel/NF-B and IB families are involved in the development of leukemias and lymphomas (22) . The genes encoding c-rel, bcl-3, nfkb1, and nfkb2 have been shown to be located at sites of recurrent genomic rearrangements in these lymphoid cancers (22, 23, 24, 25, 26) . Carried by a highly oncogenic retrovirus, v-rel causes aggressive tumors in young birds and is able to transform avian lymphoid cells and fibroblasts (27 , 28) . The mutated c-rel oncogene also transforms cells (29) . Furthermore, the expression of IB antisense resulted in constitutive activation of RelA and oncogenic transformation of NIH/3T3 cells (30) , suggesting that relA is an oncogene. A number of reports have shown that activation of NF-B may be critically involved in tumorigenesis. The Tax protein from the human T-cell leukemia virus (HTLV-1) is a potent activator of Rel/NF-B, and the growth of Tax-induced tumors in mice was inhibited by antisense relA constructs (31) . Ras and the MAP kinases are involved in the activation of Rel/NF-B transcription factors (32 , 33) . However, activation of NF-B RelA in nonlymphoid human cancers has not been identified previously. The signal cascades leading to RelA activation and RelA downstream target genes that are relevant to tumorigenesis remain unclear. An interesting possibility is that mutated Ras may involve activation of Rel/NF-B (34) . We therefore undertook a study to determine the activity of NF-B RelA transcription factors in pancreatic adenocarcinoma cells in which oncogenic activation of the K-ras gene by mutation has been identified frequently (85%; Ref. 35 ).

	Materials and Methods

Top ABSTRACT INTRODUCTION Materials and Methods RESULTS DISCUSSION REFERENCES

 
Pancreatic Tissues, Cell Lines, and Cell Culture.
Tissue samples from patients with adenocarcinoma of the pancreas were obtained at the time of surgery and were histologically confirmed to be adenocarcinoma. Histologically normal pancreas was also obtained from the region of the pancreatic neck, proximal to the site of tumor. All human pancreatic cell lines (MDAPanc-3, MDAPanc-28, MDAPanc-48, ASPC-1, BXPC-3, Capan-1, Capan-2, CFPAC-1, Hs766T, MiaCaPa-2, and Panc-1) were grown in the original cell culture medium specified by American Type Culture Collection (Rockville, MD) and DMEM containing 10% FCS. Human pancreatic tumor cell lines MDAPanc-3, MDAPanc-28, and MDAPanc-48 were established by M. Frazier and D. B. Evans (M. D. Anderson Cancer Center). SGH cell lines CK2, CK4, and Pan-1 and other immortalized/nontumorigenic cell lines were provided by P. M. Pour and T. Lawson (University of Nebraska, Omaha, NE). These cells were grown in DMEM/F12 containing 10% Nuserum IV, 1 µM dexamethasone, 2 µg/ml insulin, 10 ng/ml epidermal growth factor, 20 µg/ml bovine pituitary extract, 100 units/ml penicillin, and 100 µg/ml streptomycin.

Immunohistochemistry.
Formalin-fixed, paraffin-embedded adenocarcinoma tissues were obtained at the time of pancreatectomy from patients at our institution. Immunohistochemistry for specific detection of activated RelA was performed using monoclonal anti-human RelA antibody that recognizes an epitope overlapping the nuclear localization signal and IB binding site of RelA (CDTDDRHRIEEKRKRKT; Boehringer Mannheim, Indianapolis, IN). A control peptide was synthesized (CDTDDRHRIEEKRK-RKT) for competition assays. For detecting RelA proteins, polyclonal anti-RelA antibody that recognizes an epitope corresponding to amino acids 3–19 in the NH₂-terminal domain of RelA (Santa Cruz Biotechnology, Santa Cruz, CA) and a control peptide (amino acids 3–19) were used. Immunohistochemical staining was performed as described previously (36) .

Nuclear Extract Preparation and Electrophoretic Mobility Shift Assay.
The pancreatic cell lines were treated with TPA (50 ng/ml) or TNF- (5 ng/ml) for 60 min. Some of the pancreatic cells were treated with N-tosyl-L-phenylalanine chloromethyl ketone (50 µM) for 1 h and curcumin (50 µM) for 6 h. The nuclear extracts were prepared according to the method of Andrews and Faller (37) . The concentration of the extracts was 5 mg/ml. For EMSAs, 10 µg of nuclear extract were incubated with 1 µg poly(deoxyinosinic-deoxycytidylic acid) (Pharmacia) in a binding buffer [75 mM NaCl, 15 mM Tris (pH 7.5), 1.5 mM EDTA, 1.5 DTT, 25% glycerol, and 20 µg BSA] for 30 min at 4°C. ³²P-Labeled double-stranded oligonucleotides (5'-CTCAACAGAGGGGACTTTCCGAGAGGCCAT-3') containing the B site found in the HIV long terminal repeat were used as probes. The mutant B site for HIV long terminal repeat (5'-CTCAACAGAGTTGACTTTTCGAGAGGCCAT-3') was used for competition studies. The competition was performed with a 50-fold excess of unlabeled wild-type or mutant B oligonucleotides. The supershift experiments were performed with anti-RelA antibody in the absence or presence of the control peptide (Santa Cruz Biotechnology, Santa Cruz, CA). The binding of the probe was performed for 20 min at room temperature in a total volume of 15 µl. The reactions were analyzed on 4% polyacrylamide gels containing 0.25x TBE (Tris/borate/EDTA) buffer.

Northern Blot Analysis.
The cells stimulated by either TPA or TNF- for 1 h were harvested at the same time intervals as in EMSA, and RNA was isolated as described by Chomczynski and Sacchi (38) . RNA (25 µg) was electrophoresed through a 1.2% agarose gel containing formaldehyde, transferred to a Hybond nylon filter (MSI), and UV cross-linked. The blots were hybridized with a ³²P-labeled 1.1-kb human IB (MAD3) cDNA (EcoRI-EcoRI) probe, exposed, stripped, and rehybridized with the cDNA probe for glyceraldehyde-3-phosphate dehydrogenase as described previously (10) .

Western Blot Analysis.
Histologically normal and adenocarcinoma cells of the pancreas that were obtained and frozen at the time of surgery were ground into fine powder in liquid nitrogen, lysed, and homogenized in 250 µl of lysing buffer. Twenty-five µg of the lysates were resolved by SDS-PAGE, transferred to nylon membranes (Immobilon-P; Millipore, Bedford, MA), and detected with IB antibody specific for the NH₂ terminus (amino acids 1–56) of the IB protein. The subsequent Western blot analysis was carried out with an ECL western blotting kit (Amersham) according to the manufacturer’s recommendations.

CAT Assay.
One µg of the HIV B-CAT reporter plasmid, 2.5 µg of ß-actin promoter LacZ expression plasmids, and 5 µg of IBM, RafDN, MEKK1DN, and CMVpBS (control) expression plasmids were used in each cotransfection. Forty-eight h after lipotransfection, the cells were collected. Relative transfection efficiency was determined by cotransfected LacZ expression plasmid, and subsequent ß-galactosidase activities in cell extracts were used to normalize the transfection efficiencies. CAT assays were performed as described previously (10) , and CAT activity (percentage of conversion to acetylated chloramphenicol) was determined by phosphoimage analysis.

	RESULTS

Top ABSTRACT INTRODUCTION Materials and Methods RESULTS DISCUSSION REFERENCES

 
To investigate whether Rel/NF-B-DNA binding activities were altered in human pancreatic adenocarcinoma, we first carried out immunohistochemical analyses. The monoclonal antibodies (Boehringer Mannheim) used in this study detect only activated RelA proteins (36) . They do this by recognizing an epitope overlapping the nuclear localization signal and IB binding site of RelA. Therefore, these monoclonal antibodies can selectively and specifically bind to the activated form of RelA (36) and are useful in differentiating between activated and inactivated forms of RelA. When the affinity-purified monoclonal antibodies, which detect only the activated RelA proteins, were used in the analysis, specific RelA staining was detected in 16 of 24 pancreatic adenocarcinomas but not in normal human pancreatic ductal epithelial cells or surrounding fibroblastic stroma (Fig. 1, A and B) . The staining for RelA was competed away using the control peptide (Fig. 1C) . Similar levels of RelA proteins were detected by the polyclonal rabbit anti-RelA antibodies, which recognize all of the RelA proteins, in both normal human pancreatic ductal epithelial cells and pancreatic adenocarcinoma (data not shown). These results show that RelA is activated in human pancreatic adenocarcinoma cells but not in the normal pancreatic ductal cells.

View larger version (85K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. Immunohistochemical detection of activated RelA in paired normal and tumor pancreatic tissue. Twenty-four paired normal and tumor pancreatic tissue samples were subjected to immunohistochemical analysis using a RelA monoclonal antibody specific for the activated RelA protein. The subsequent analysis was carried out as described previously (36) . A, normal pancreas tissues; B, pancreatic adenocarcinoma; and C, pancreatic adenocarcinoma with the control peptide were probed with the anti-RelA antibody specific for activated RelA. Representative fields are shown above.

View larger version (46K): [in this window] [in a new window] [Download PPT slide]   Fig. 2. RelA activity in nuclear extracts isolated from paired normal and tumor pancreatic tissue samples. A, nuclear extracts (50 µg) were used in EMSA to determine the RelA-DNA binding activity in paired normal (N) and tumor (T) pancreatic tissues (paired Lanes 1–8), using the HIV B oligonucleotides as probes. B, the nuclear extracts from the tumors (paired Lanes 1 and 2) were used in competition with a 50-fold excess of unlabeled wild-type or mutant B oligonucleotides and in supershift with anti-RelA antibody in the absence or presence of the control peptide. Arrow, supershift complex. In C, cytoplasmic extracts (25 µg) were used in Western blot analysis with IB antibody specific for the NH2 terminus (amino acids 1–56) of IB protein. The subsequent Western blot analysis was carried out with the ECL Western blotting kit described in "Materials and Methods" (10) .

To determine whether RelA-DNA binding activity also was activated in human and SGH pancreatic adenocarcinoma cell lines, we performed EMSA using the nuclear extracts from control cells (Jurkat cells stimulated with 50 µg/ml TPA), human pancreatic adenocarcinoma cell lines, the tumorigenic SGH pancreatic cell line Pan-1, and nontumorigenic SGH pancreatic cell lines CK2 and CK4. Our results show that constitutive RelA activation was detected in the human pancreatic tumor cell lines MDAPanc-28, MDAPanc-48, Capan-1, Capan-2, Panc-1, BxPC-3, MiaCaPa-2, AsPC-1, CFPAC-1, and SGH pancreatic tumor cell line Pan-1 but not in human pancreatic tumor cell lines MDAPanc-3 and Hs766T or in nontumorigenic SGH cell lines CK2 and CK4. Fig. 3 shows examples of RelA activity in the pancreatic cell lines that we studied. Constitutive RelA DNA binding activity was detected in the human pancreatic tumor cell lines CFPAC-1, Capan-1, BxPC-3, AsPC-1, and SGH pancreatic tumor cell line Pan-1 but not in nontumorigenic SGH cell lines CK2 and CK4 (Fig. 3A) . The RelA-DNA binding activity was further characterized with or without phorbol myristate acetate and TNF- stimulation in six human pancreatic tumor cell lines. Fig. 3 B shows that stimulation of MDAPanc-28, Capan-1, AsPC-1, CFPAC-1, and BxPC-3 cells with phorbol myristate acetate (50 µg/ml) or TNF- (5 ng/ml) did not further induce RelA-DNA binding activity, indicating that the RelA was already activated. In HS766T cells, RelA activity was inducible by TPA or TNF- (Fig. 3B) . When unlabeled wild-type and mutant B oligonucleotides were used in competition and the anti-RelA specific antibody was used in EMSA supershifts, the results indicated that the binding activities in the extracts were specific to B sites and RelA (Fig. 3C) . No differences in oct-1 and AP-1 DNA binding activities were detected in these pancreas cancer cell lines tested, in which RelA is constitutively activated and in MDAPanc-3 cells, one of the two human pancreatic cancer cell lines with inducible RelA activity (data not shown). The results obtained from further analyses were consistent with RelA activation being detected by multiple gel-shift analyses of independent samples at different passages in the original cell-culture medium specified by American Type Culture Collection and in DMEM containing 10% FCS (data not shown). Thus, we have concluded that RelA is constitutively activated in most pancreatic tumors but not in normal pancreatic tissues and nontumorigenic SGH pancreatic cells and that constitutive activation of RelA is a stable alteration in these pancreatic adenocarcinoma cells. These cell lines have provided a useful in vitro system for studying the signal transduction pathway leading to constitutive RelA activation and the role of constitutively activated RelA in pancreatic adenocarcinoma.

View larger version (41K): [in this window] [in a new window] [Download PPT slide]   Fig. 3. RelA activity in tumorigenic and nontumorigenic pancreatic cell lines. Control cells were treated with TPA (50 µg/ml) or with TNF- (5 ng/ml). In A and B, nuclear extracts (10 µg) were subjected to EMSA to determine the RelA-DNA binding activity in tumorigenic human and SGH pancreatic cell lines and nontumorigenic SGH pancreatic cell lines as indicated. In C, nuclear extracts from MDAPanc-28 and control Jurkat cells were subjected to EMSA for competition with a 50-fold excess of unlabeled wild-type or mutant B oligonucleotides and for supershift using anti-RelA antibody with or without control peptide. The HIV B oligonucleotides were used as probes. Arrow, supershift complex. D, expression of IB in human pancreatic tumor cell lines. Total RNA or cytoplasmic extracts were isolated from the cell lines as indicated with or without treatment with TPA (50 µg/ml) or TNF- (5 µg/ml). Total RNA (25 µg) was used in Northern blot analysis. The blots were hybridized with a human IB (MAD3) cDNA probe, exposed, stripped, and rehybridized with the cDNA probe for glyceraldehyde-3-phosphate dehydrogenase (data not shown).

Curcumin, a potent antioxidant and cancer chemopreventive agent, has been shown to inhibit kinase activity and TNF--induced activation of NF-B at a step before the phosphorylation of IB (41 , 42) . We therefore examined the effect of curcumin on constitutive RelA activity in the human pancreatic tumor cell line MDAPanc-28. Our data showed that constitutive RelA-DNA binding activity in pancreatic cancer cells was totally inhibited by curcumin (25 µM), as evidenced by the complete absence of such B-specific DNA binding activity in extracts from cell lines after 6 h of treatment, whereas there was no reduction of RelA-DNA binding activity in control cells with or without DMSO treatment (Fig. 4A) . Moreover, the constitutive RelA activity was totally inhibited by N-tosyl-L-phenylalanine chloromethyl ketone treatment, as we reported previously (Ref. 10 ; Fig. 4 A). These results suggest that the constitutive RelA activity in pancreatic adenocarcinoma cells is induced by the activation of the upstream signal-transduction cascades leading to activation of RelA.

View larger version (55K): [in this window] [in a new window] [Download PPT slide]   Fig. 4. A, inhibition of RelA-DNA binding activity by curcumin. MDAPanc-28 cells were grown to 80% confluence and treated with various concentrations of curcumin for 6 h as indicated. Nuclear extracts (10 µg) were used in EMSA to determine the RelA-DNA binding activity in the cell lines treated with or without curcumin. B, inhibition of constitutive RelA activity by dominant-negative IB, c-Raf, and MEKK1. CAT assays for analysis of B reporter gene activities were performed as described previously (10) . The B reporter gene plasmids were cotransfected into MDAPanc-28 and Capan-1 cells with various expression plasmids as indicated. The transfected cells were harvested, the relative transfection efficiencies were determined by using the cotransfected LacZ expression plasmid (1 µg, CMV-LacZ), and subsequent ß-galactosidase activities in the cell extracts were very similar and used to normalize the transfection efficiencies. The results shown here are representative of five CAT assays. ß-gl, ß-galactosidase; WT, wild type. C, the ß-actin promoter/ß-galactosidase reporter gene plasmid was cotransfected into MDAPanc-28 and Capan-1 cells with various expression plasmids as indicated, and the relative transfection efficiencies were determined by using the cotransfected luciferase expression plasmid (1 µg, TK-Renilla luciferase), and subsequent ß-galactosidase (ß-gal) and Renilla luciferase (R. luc.) activities in the cell extracts were determined. Renilla luciferase activities were used to normalize the transfection efficiencies. Bars, SD. In D, inhibition of RelA activity by curcumin potentiates apoptotic cell death induced by Taxol. Twenty thousand cells/well were seeded in 96-well plates. After 8 h of incubation, cells in triplicate were either left untreated or treated with curcumin (50 µM), Taxol (10 µM), or both. At various time points as indicated, surviving cells were quantified by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays. Bars, SD.

IB, c-Raf

IB, Raf

To determine the effect of curcumin on the growth of pancreatic cancer cells, we treated MDAPanc-28 cells with or without Taxol, a chemotherapy agent used in treatment of pancreatic cancer and a known apoptotic inducer, in the presence and absence of curcumin. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was used to determine the percentage of viable cells at the end of each time point. The results shown in Fig. 4D indicated that curcumin did not inhibit the growth of MDAPanc-28 cells, but curcumin-mediated inhibition of RelA activity may sensitize these cells to Taxol-induced apoptosis. Our finding is consistent with the previous reports that RelA plays a key role in regulation of apoptosis (43 , 44 , 49) .

	DISCUSSION

Top ABSTRACT INTRODUCTION Materials and Methods RESULTS DISCUSSION REFERENCES

 
We have demonstrated that RelA-DNA binding activity is constitutively activated in the majority of human pancreatic adenocarcinomas and human and SGH pancreatic adenocarcinoma cell lines but not in normal pancreatic tissues or the nontumorigenic SGH pancreatic cell lines tested. RelA may be constitutively activated in pancreatic tumor cells by upstream signaling cascades, possibly involving Ras and MAP kinases.

In our immunohistochemical analyses for detecting Rel/NFB-DNA binding activities in human pancreatic adenocarcinoma, the monoclonal antibodies detected the activated RelA proteins only by recognizing an epitope overlapping the nuclear localization signal and IB binding site of RelA and therefore selectively and specifically bound to the activated form of RelA (36) . This selectivity and specificity of the monoclonal antibody were characterized previously, and it has been shown that these monoclonal antibodies cannot bind to RelA proteins when they are associated with the inhibitor IB (36) . In our early studies of constitutive Rel/NFB activity in B cells undergoing differentiation (6 , 11) , we found that only 10–20% of total Rel/NFB proteins were detectable in the nucleus. It is unclear why the majority of Rel/NFB proteins that are freed from IB remain in the cytoplasm (6) . Because only 10–20% of RelA proteins can be localized in the nucleus and 80–90% of RelA still remain in the cytoplasm when RelA proteins are activated constitutively by long-term stimulation (11) , this monoclonal anti-RelA antibody was useful in differentiating between activated and inactivated forms of RelA and facilitated the detection of the activated RelA proteins. Our data from immunohistochemical analyses showed that RelA was constitutively activated in human pancreatic adenocarcinoma. The conclusion is further supported by the detection of RelA-DNA binding activity in the nucleus of pancreatic adenocarcinoma, but not in normal pancreatic tissues, and by the detection of overexpressed IB protein in pancreatic adenocarcinoma but not in normal pancreatic tissues.

The subsequent analyses also show constitutive RelA activity in nine human pancreatic tumor cell lines and in the SGH pancreatic tumor cell line Pan-1 but not in the immortalized/nontumorigenic SGH cell lines CK2 and CK4, which were used to compensate for the lack of nontumorigenic human pancreatic ductal cell lines. The tumorigenic pancreatic ductal epithelial cell lines from SGH, with similarities in pathology, morphology, and molecular alterations to human pancreatic cancer, provide a biologically relevant in vivo model for analyzing the molecular alterations in signal transduction cascades (45 , 46) . These results raise the interesting possibility that RelA is an oncogene and that its constitutive activity plays a critical role in pancreatic tumorigenesis. Recently, others have shown that constitutive activation of RelA and oncogenic transformation have been achieved by the expression of IB antisense in NIH/3T3 cells (30) .

Little is known about the involvement of Rel/NFB transcription factors and their inhibitor IB in oncogenesis of nonlymphoid cancers. Thus far, only three reported cases of the alteration in expression of Rel/NF-B have been associated with nonlymphoid cancers. p65, p52 (p100), and p50 (p105) proteins are highly expressed in some breast and lung cancers (22 , 47) . However, no alterations in B DNA binding activity associated with overexpressed Rel/NF-B proteins have been demonstrated previously. It has been shown that overexpression of RelA in transgenic mouse thymocytes specifically increased the level of inhibitor IB but not the overall NF-B-binding activity in unstimulated cells when compared with those of control thymocytes (48) . These results indicate that cytoplasmic retention of overexpressed RelA by IB is the major in vivo mechanism controlling the potential excess of NF-B activity in long-term RelA-overexpressing cells and explain why overexpression of RelA, RelB, and c-Rel does not induce tumors in transgenic mice. The constitutive RelA activity induced by the antisense expression of inhibitor IB has been reported to transform NIH/3T3 cells, demonstrating that RelA is also a transforming gene besides mutated c-Rel and v-Rel (30) . However, the fibroblast cell lines established from the IB knockout mice, which exhibited constitutive RelA activity and a postneonatal lethal phenotype, were not transformed (49) , suggesting that constitutive activation of RelA alone was unable to transform murine fibroblast cells and may require a cooperating oncogene such as ras for tumorigenic transformation. A recent report showed that activation of RelA by oncogenic Ha-ras-induced signaling is required for cellular transformation (50) . This report supports the possibility that the Ras and MAP kinase signal transduction pathway is involved in the constitutive activation of RelA in pancreatic tumor cells.

Possible explanations for the constitutive RelA activity in pancreatic cancer cells are: (a) IB is mutated and therefore cannot bind to RelA and mask the nuclear translocation signal in RelA; (b) mutations in RelA prohibit IB binding to RelA; or (c) the RelA upstream signal-transduction cascades are constitutively activated. Our data demonstrate that constitutive RelA activity in MDAPanc-28 cells can be inhibited by the nonspecific kinase inhibitor, curcumin. Curcumin inhibits TNF--induced activation of NFB at a step before IB phosphorylation (41) . Our data also show that expression of dominant-negative IB, Raf, and MEKK1 resulted in almost complete inhibition of constitutive RelA-activated transcription specifically through B sites in MDAPanc-28 and Capan-1 cells (Fig. 4) . These results suggest that constitutive RelA activity in pancreatic adenocarcinoma cells is induced through activation of upstream signal-transduction cascades for RelA. If constitutive RelA activity is caused by a mutation in either IB or RelA that prohibits their interaction, the constitutive RelA activity would not be inhibited by blocking the upstream signaling pathways using curcumin or expression of dominant-negative IB, Raf, and MEKK1. Additionally, these results suggest that MAP kinase signaling cascades are involved in the constitutive activation of RelA in pancreatic tumors, possibly involving mutated K-ras.

Ras initiates two divergent signaling cascades that activate distinct MAP kinases. Activation of ERKs by Ras is mediated via Raf-1 and MEK kinases, whereas JNK activation is mediated by another Ras-responsive protein kinase, MEKK (51 , 52) . Recent reports showed that Raf-1 is commonly used by multiple inducers that activate Rel/NF-B (33) and that MEKK1 has been identified as one of the tightly associated subunits in IB kinase complex and phosphorylates the IB kinase complex, which, in turn, phosphorylates IB proteins and activates Rel/NF-B transcription factors (15, 16, 17, 18, 19, 20, 21) . These results are consistent with the possibility that Ras and MAP kinases are involved in constitutive activation of RelA in pancreatic tumor cells. Our results suggest that point mutation in the ras oncogene might correlate with the constitutive RelA activity in pancreatic cancers. Activated RelA was detected in 65% (13 of 20) of the pancreatic adenocarcinoma tissues that were shown previously to carry a K-ras mutation at codon 12 (39 , 40) , and 89% (8 of 9) human pancreatic tumor cell lines that carry the same mutated K-ras gene have constitutive RelA activity. However, despite this correlation, of the 11 human pancreatic tumor cell lines that we studied, both BxPc3 and HS766T cells express a wild-type K-ras gene. For BxPc3 cells, RelA is constitutively activated (Fig. 3, A and B) , and for HS766T cells, RelA activity is inducible (Fig. 3B) . MDAPanc-3 cells, which carry a mutated K-ras gene, also has inducible RelA activity (data not shown). It is possible that signal transducers upstream or downstream of K-ras are constitutively activated in BxPc3 cells, and additional genetic alterations might be needed to activate RelA in HS766T and MDAPanc-3 cells. The mechanisms for constitutive activation of RelA in pancreatic cancer remain unknown. Determination of the activities of IB kinases, Ras, and MAP kinases from these pancreatic tumor cell lines and expression of a transfected mutated K-ras gene, raf-1, MEKK1, and IKKs into nontumorigenic SGH cells will help to elucidate the signal-transduction pathways leading to the constitutive activation of RelA in pancreatic adenocarcinomas.

	ACKNOWLEDGMENTS

 
We are grateful to Drs, Inder M. Verma and Dan Van Antwerp at the Salk Institute for IBM expression plasmid; to Dr. Bin Su in the Department of Immunology at University of Texas M. D. Anderson Cancer Center for RafDN and MEKK1DN; to Dr. Marsha L. Frazier in the Department of Gastrointestinal Oncology at University of Texas M. D. Anderson Cancer Center for providing MDAPanc-3, MDAPanc-28, and MDAPanc-48 cell lines; and to Drs. Terry Lawson and Coral Kolar at Eppley Institute for Cancer Research, the University of Nebraska, for providing SGH pancreatic cell lines. We thank Di Shen for technical assistance, members of the Chiao laboratory for helpful discussions, and Nancy G. Arora and Pat Thomas for editorial assistance.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported in part by grants from the University Cancer Foundation, PRS at M. D. Anderson Cancer Center and National Cancer Institute CA73675-01.

² To whom requests for reprints should be addressed, at Department of Surgical Oncology/Tumor Biology, Box 107, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 794-1030; Fax: (713) 794-4830; E-mail: pjchiao{at}notes.mdacc.tmc.edu

³ The abbreviations used are: NF, nuclear factor; TNF, tumor necrosis factor; MAP, mitogen-activated protein; SGH, Syrian golden hamster; TPA, tetradecanoylphorbol-13-acetate; EMSA, electrophoretic mobility shift assay; CAT, chloramphenicol acetyltransferase; CMV, cytomegalovirus.

Received 7/31/98; revised 10/14/98; accepted 10/27/98.

	REFERENCES

Top ABSTRACT INTRODUCTION Materials and Methods RESULTS DISCUSSION REFERENCES

 

1. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1997. CA Cancer J. Clin., 47: 5-27, 1997.[Medline]
2. DiGiuseppe J. A., Yeo C. J., Hruban R. H. Molecular biology and the diagnosis and treatment of adenocarcinoma of the pancreas. Adv. Anat. Pathol., 3: 139-155, 1996.
3. Staley C. A., Lee J. E., Cleary K. A., Abbruzzese J. L., Ames F. C., Fenoglio C., Evans D. B. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head: patient survival and patterns of treatment failure. Am. J. Surg., 171: 118-124, 1996.[Medline]
4. Evans D. B., Abbruzzese J. L., Lee J. E., Leach S. D., Charnsangavej C., Cleary K. R., Buchholz D. J., Rich T. A. Preoperative chemoradiation for adenocarcinoma of the pancreas: MD Anderson experience. Semin. Surg. Oncol., 11: 132-142, 1995.
5. Hahn S. A., Schutte M., Shamsul Hoque A. T. M., Moskaluk C. A., DaCosta L. T., Rozenblum E., Weinstein C. L., Fischer A., Yeo C. J., Hruban R. H., Kern S. E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (Washington DC), 271: 350-353, 1996.[Abstract]
6. Verma I. M., Stevenson J. K., Schwarz E. M., Antwerp D. V., Miyamoto S. Rel/NF-B/IB family: intimate tales of association and dissociation. Genes Dev., 9: 2723-2735, 1995.[Free Full Text]
7. Baldwin A., Jr. The NF-B and IB proteins: new discoveries and insights. Annu. Rev. Immunol., 14: 694-681, 1996.
8. Bacuerle P. A., Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science (Washington DC), 242: 540-546, 1988.[Abstract/Free Full Text]
9. Grilli M., Chiu J. J. S., Lenardo M. J. NF-kappa B and Rel: participants in a multiform transcriptional regulatory system. Int. Rev. Cytol., 143: 1-62, 1993.[Medline]
10. Chiao P. J., Miyamoto S., Verma I. M. Autoregulation of IB activity. Proc. Natl. Acad. Sci. USA, 91: 28-33, 1994.[Abstract/Free Full Text]
11. Miyamoto S., Chiao P. J., Verma I. M. Enhanced IB degradation is responsible for constitutive NF-B activity in mature murine B-cell lines. Mol. Cell. Biol., 14: 3276-3282, 1994.[Abstract/Free Full Text]
12. Brown K., Gerstberger S., Carlson L., Franzoso G., Siebenlist U. Control of IB proteolysis by site-specific, signal-induced phosphorylation. Science (Washington DC), 267: 1485-1488, 1995.[Abstract/Free Full Text]
13. Chen Z. J., Hagler J., Palombella V. J., Melandri F., Scherer D., Ballard D., Maniatis T. Signal-induced site-specific phosphorylation targets IB to the ubiquitin-proteasome pathway. Genes Dev., 9: 1586-1597, 1995.[Abstract/Free Full Text]
14. Didonato J. A., Mercurio F., Karin M. Phosphorylation of IB precedes but is not sufficient for its dissociation from NF-B. Mol. Cell Biol., 15: 1302-1311, 1995.[Abstract]
15. Mercurio F., Zhu H., Murray B. W., Shevchenko A., Bennett B. L., Li J., Young D. B., Barbosa M., Mann M., Manning A., Rao A. IKK-1, and IKK-2: cytokine-activated IB kinases essential for NF-B activation. Science (Washington DC), 278: 860-866, 1997.[Abstract/Free Full Text]
16. Woronicz J. D., Gao X., Cao Z., Rothe M., Goeddel D. V. IB kinase-ß: NF-B activation and complex formation with IB kinase- and NIK. Science (Washington DC), 278: 866-869, 1997.[Abstract/Free Full Text]
17. DiDonato J. A., Hayakawa M., Rothwarf D. M., Zandi E., Karin M. A cytokine-responsive IB kinase that activates the transcription factor NF-B. Nature (Lond.), 388: 548-554, 1997.[Medline]
18. Regnier C. H., Song H. Y., Gao X., Goeddel D. V., Cao Z., Rothe M. Identification and characterization of an IB kinase. Cell, 90: 373-383, 1997.[Medline]
19. Zandi E., Rothwarf D. M., Delhase M., Hayakawa M., Karin M. The IB kinase complex (IKK) contains two kinase subunits, IKK and IKKß, necessary for IB phosphorylation and NF-B activation. Cell, 91: 243-252, 1997.[Medline]
20. Hirano M., Osada S., Aoki T., Hirai S., Hosaakka M., Inoue J., Ohno S. MEK kinase is involved in tumor necrosis factor -induced NF-B activation and degradation of IB. J. Biol. Chem., 271: 13234-13238, 1996.[Abstract/Free Full Text]
21. Lee F. S., Hagler J., Chen Z., Maniatis T. Activation of the IB kinase complex by MEKK1, a kinase of the JNK pathway. Cell, 88: 213-222, 1997.[Medline]
22. Gilmore T. D., Koedood M., Piffat K. A., White D. Rel/NF-B/IB proteins and cancer. Oncogene, 14: 1367-1378, 1997.
23. Neri A., Chang C. C., Lombardi L., Salina M., Corradini P., Maiolo A. T., Chaganti R. S. K., Dalla-Favera R. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-B p50. Cell, 67: 1075-1087, 1991.[Medline]
24. Liptay S., Schmid R. M., Perkins N. D., Meltzer P., Altherr M. R., McPherson J. D., Wasmuth J. J., Nabel G. J. Related subunits of NF-B map to two distinct loci associated with translocations in leukemia: NFKB1 and NFKB2. Genomics, 13: 287-292, 1992.[Medline]
25. Ohno H., Takimoto G., McKeithan T. W. The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell, 60: 991-997, 1990.[Medline]
26. Lu D., Thompson J. D., Gorski G. K., Rice N. R., Mayer M. G., Yunis J. J. Alterations of the rel locus in human lymphoma. Oncogene, 6: 1235-1241, 1991.[Medline]
27. Moore B. E., Bose H. R. Transformation of avian lymphoid cells by reticuloendotheliosis virus. Mutat. Res., 195: 79-80, 1988.[Medline]
28. Moore B. E., Bose H. R. J. Expression of the v-rel oncogene in reticuloendotheliosis virus-transformed fibroblasts. Virology, 162: 377-387, 1988.[Medline]
29. Sylla B. S., Temin H. M. Activation of oncogenicity of the c-rel proto-oncogene. Mol. Cell. Biol., 6: 4709-4716, 1986.[Abstract/Free Full Text]
30. Beauparlant P., Kwan I., Bitaar R., Chou P., Koromilas A. E., Sonenberg N., Hiscott J. Disruption of IB regulation by antisense RNA expression leads to malignant transformation. Oncogene, 9: 3189-3197, 1994.[Medline]
31. Kitajima I., Shinohara T., Bilakovics J. D. A. B., Xu X., Nerenberg M. Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-B. Science (Washington DC), 258: 1792-1795, 1992.[Abstract/Free Full Text]
32. Finco T. S., Baldwin A. S., Jr. Kappa B site-dependent induction of gene expression by diverse inducers of nuclear factor kappa B requires Raf-1. J. Biol. Chem., 268: 17676-17679, 1993.[Abstract/Free Full Text]
33. Bruder J. T., Heidecker G., Tan T. H., Weske J. C., Derse D., Rapp U. R. Oncogene activation of HIV-LTR-driven expression via the NF-kappa B binding sites. Nucleic Acids Res., 21: 5229-5234, 1993.[Abstract/Free Full Text]
34. Mayo M. W., Wang C. Y., Cogswell P. C., Rogers-Graham K. S., Lowe S. W., Der C. J., Baldwin A. S., Jr. Requirement of NF-B activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science (Washington DC), 278: 1812-1815, 1997.[Abstract/Free Full Text]
35. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. Most human carcinomas of the human exocrine pancreas contain mutant c-K-ras genes. Cell, 53: 549-554, 1988.[Medline]
36. Zable U., Henkel T., Silva M. D. S., Bacuerle P. Nuclear uptake control of NF-B by MAD-3, an IB protein in the nucleus. EMBO J., 12: 201-211, 1993.[Medline]
37. Andrews N. C., Faller D. V. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res., 19: 2499 1991.[Free Full Text]
38. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.[Medline]
39. Abbruzzese J. L., Evans D. B., Raijman I., Larry L., King T., Leach S. D., Frazier M. L. Detection of mutated c-Ki-ras in the bile of patients with pancreati cancer. Anticancer Res., 17: 795-801, 1997.[Medline]
40. Evans D. B., Frazier M. L., Charnsangavej C., Katz R. L., Larry L., Abbruzzese J. L. Molecular diagnosis of exocrine pancreatic cancer using a percutaneous technique. Ann. Surg. Oncol., 3: 241-246, 1996.[Abstract]
41. Singh S., Aggarwal B. B. Activation of transcription factor NF-B is suppressed by curcumin (diferuloylmethane). J. Biol. Chem., 270: 24995-25000, 1995.[Abstract/Free Full Text]
42. Korutla L., Kumar R. Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells. Biochim. Biophys. Acta, 1224: 597-600, 1994.[Medline]
43. Wang C. Y., Mayo M. W., Baldwin A., Jr. TNF- and cancer therapy-induced apoptosis potentiation by inhibition of NF-B. Science (Washington DC), 274: 784-787, 1996.[Abstract/Free Full Text]
44. Van Antwerp D., Martin S. J., Kafri T., Green D. R., Verma I. M. Suppression of TNF--induced apoptosis by NF-B. Science (Washington DC), 274: 787-789, 1996.[Abstract/Free Full Text]
45. Hall P. A., Lemoine N. R. Models of pancreatic cancer. Cancer Surv., 16: 135-155, 1993.[Medline]
46. Longnecker D. S., Wiebikin N. M., Schaeffer B. K., Roebuck B. D. Experimental carcinogenesis in the pancreas. Int. Rev. Exp. Pathol., 26: 177-229, 1984.[Medline]
47. Sovak M. A., Bellas R. E., Kim D. W., Zanieski G. J., Rogers A. E., Traish A. M., Sonenshein G. E. Aberrant nuclear factor-B/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest., 100: 2952-2960, 1997.[Medline]
48. Perez P., Lira S. A., Bravo R. Overexpression of RelA in transgenic mouse thymocytes: specific increase in levels of the inhibitor protein I kappa B. Mol. Cell. Biol., 7: 3523-3530, 1995.
49. Beg A. A., Baltimore D. An essential role of NF-B in preventing TNF--induced cell death. Science (Washington DC), 274: 782-784, 1996.[Abstract/Free Full Text]
50. Finco T. S., Westwick J. K., Norris J. L., Beg A. A., Der C. J., Baldwin A. S., Jr. Oncogenic Ha-Ras-induced signaling activates NF-B transcriptional activity, which is required for cellular transformation. J. Biol. Chem., 272: 24113-24116, 1997.[Abstract/Free Full Text]
51. Minden A., Lin A., McMahon M., Lange-Carter C., Derijard B., Davis R. J., Johnson G. L., Karin M. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science (Washington DC), 266: 1719-1723, 1997.
52. Russell M., Lange-Carter C. A., Johnson G. L. Direct interaction between Ras and the kinase domain of mitogen-activated protein kinase (MEKK1). J. Biol. Chem., 270: 11757-11760, 1995.[Abstract/Free Full Text]

This article has been cited by other articles:

				A. B. Kunnumakkara, H. Ichikawa, P. Anand, C. J. Mohankumar, P. S. Hema, M. S. Nair, and B. B. Aggarwal Coronarin D, a labdane diterpene, inhibits both constitutive and inducible nuclear factor-{kappa}B pathway activation, leading to potentiation of apoptosis, inhibition of invasion, and suppression of osteoclastogenesis Mol. Cancer Ther., October 1, 2008; 7(10): 3306 - 3317. [Abstract] [Full Text] [PDF]

				S. A. Danovi, H. H. Wong, and N. R. Lemoine Targeted therapies for pancreatic cancer Br. Med. Bull., September 1, 2008; 87(1): 97 - 130. [Abstract] [Full Text] [PDF]

				C. M. Sloss, F. Wang, R. Liu, L. Xia, M. Houston, D. Ljungman, M. A. Palladino, and J. C. Cusack Jr. Proteasome Inhibition Activates Epidermal Growth Factor Receptor (EGFR) and EGFR-Independent Mitogenic Kinase Signaling Pathways in Pancreatic Cancer Cells Clin. Cancer Res., August 15, 2008; 14(16): 5116 - 5123. [Abstract] [Full Text] [PDF]

				N. Dhillon, B. B. Aggarwal, R. A. Newman, R. A. Wolff, A. B. Kunnumakkara, J. L. Abbruzzese, C. S. Ng, V. Badmaev, and R. Kurzrock Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer Clin. Cancer Res., July 15, 2008; 14(14): 4491 - 4499. [Abstract] [Full Text] [PDF]

				B. K. Bednarski, X. Ding, K. Coombe, A. S. Baldwin, and H. J. Kim Active roles for inhibitory {kappa}B kinases {alpha} and {beta} in nuclear factor-{kappa}B-mediated chemoresistance to doxorubicin Mol. Cancer Ther., July 1, 2008; 7(7): 1827 - 1835. [Abstract] [Full Text] [PDF]

				S. Chumsri, W. Matsui, and A. M Burger Therapeutic Implications of Leukemic Stem Cell Pathways Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 397 - 406. [Abstract] [Full Text] [PDF]

				J. Cai, A. Razzak, J. Hering, A. Saed, T. A. Babcock, S. Helton, and N. J. Espat Feasibility Evaluation of Emodin (Rhubarb Extract) as an Inhibitor of Pancreatic Cancer Cell Proliferation In Vitro JPEN J Parenter Enteral Nutr, March 1, 2008; 32(2): 190 - 196. [Abstract] [Full Text] [PDF]

				J. L. Williams, P. Ji, N. Ouyang, X. Liu, and B. Rigas NO-donating aspirin inhibits the activation of NF-{kappa}B in human cancer cell lines and Min mice Carcinogenesis, February 1, 2008; 29(2): 390 - 397. [Abstract] [Full Text] [PDF]

				G. Sethi, B. Sung, and B. B. Aggarwal Nuclear Factor-{kappa}B Activation: From Bench to Bedside Experimental Biology and Medicine, January 1, 2008; 233(1): 21 - 31. [Abstract] [Full Text] [PDF]